Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
Top Cited Papers
- 7 January 2016
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 374 (1), 33-42
- https://doi.org/10.1056/nejmoa1511812
Abstract
In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase-chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, −7 percentage points; 95% confidence interval [CI], −18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, −3 percentage points; 95% CI, −13 to 8). No serious adverse reactions associated with the use of convalescent plasma were observed. The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival. (Funded by the European Union’s Horizon 2020 Research and Innovation Program and others; ClinicalTrials.gov number, NCT02342171.)Keywords
This publication has 12 references indexed in Scilit:
- Ebola Virus Disease among Children in West AfricaThe New England Journal of Medicine, 2015
- Clinical Presentation of Patients with Ebola Virus Disease in Conakry, GuineaThe New England Journal of Medicine, 2015
- Clinical Illness and Outcomes in Patients with Ebola in Sierra LeoneThe New England Journal of Medicine, 2014
- Randomised controlled trials for Ebola: practical and ethical issuesThe Lancet, 2014
- Reversion of advanced Ebola virus disease in nonhuman primates with ZMappNature, 2014
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014
- Computing Adjusted Risk Ratios and Risk Differences in StataThe Stata Journal: Promoting communications on statistics and Stata, 2013
- Postexposure antibody prophylaxis protects nonhuman primates from filovirus diseaseProceedings of the National Academy of Sciences of the United States of America, 2012
- Passive antibody therapy for infectious diseasesNature Reviews Microbiology, 2004
- Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent PatientsThe Journal of Infectious Diseases, 1999